We therefore conducted a systematic review and meta-analysis of the blood levels of the astrocyte biomarkers GFAP, YKL-40, and S100B to investigate whether different stages on the AD clinical spectrum are characterized by different levels of biomarkers. The gene discussed is GFAP; the disease is Alzheimer disease.